Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

VGA039 is a first-in-class monoclonal antibody therapy with a novel mechanism of action that targets Protein S, thereby ...

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ETInitial safety data for 32 patients with autoimmune disease treated ...

HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead ...

Nitazenes, a class of synthetic drugs 40 times more potent than fentanyl, are steadily becoming more common on both sides of ...

On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted "The Asset Corporate Sustainability Leadership Awards 2025" ceremony in Singapore. Fosun International Limited ...

Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026 ...

"Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The European Medicines Agency (EMA) has granted approval to Iceland-based Arctic Therapeutics to commence a Phase IIa trial of small-molecule oral therapy, AT-001, targeting patients with Alzheimer’s ...

Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...

News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion ...